Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1426 - 1426 of 1426

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 602 of 602

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1676 - 1700 of 2138

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Status	Project Number
Mepolizumab	cdr_SR0461_Nucala.pdf SR0461_Nucala_CL_Report_e.pdf SR0461_Nucala_PE_Report_e.pdf SR0461_complete_Nucala_June-20-16_e.pdf SR0461_Nucala_PI_Submissions.pdf	Nov 20, 2015	Reimbursement Review	Complete	SR0461-000
Aflibercept	SR0460 Eylea.pdf SR0460_Eylea BRVO_complete_Jul-29_16.pdf SR0460_Eylea_BRVO_CL_Report.pdf SR0460_Eylea_BRVO_PE_Report.pdf	Nov 16, 2015	Reimbursement Review	Complete	SR0460-000
Cyramza for Advanced GC or GEJ Adenocarcinoma – Details	pcodr_profund_ramucirumab_cyramza_gc.pdf pcodr_ramucirumab_cyramza_gc_fn_rec.pdf pcodr_ramucirumab_cyramza_gc_fn_cgr.pdf pcodr_ramucirumab_cyramza_gc_fn_egr.pdf pcodr_ramucirumab_cyramza_gc_in_rec.pdf pcodr_ramucirumab_cyramza_gc-pagfdk.pdf pcodr_ramucirumab_cyramza_gc-fdk-elc.pdf	Nov 13, 2015	Reimbursement Review	Complete	PC0059-000
Avastin (with capecitabine) for Metastatic Colorectal Cancer - Details	pcodr_provfund_avastin-capecitabine_mcrc.pdf pcodr_avastin_capecitabine_mcrc_fn_rec.pdf pcodr_avastin_capecitabine_mcrc_fn_cgr.pdf pcodr_avastin_capecitabine_mcrc_fn_egr.pdf pcodr_avastin_capecitabine_mcrc_in_rec.pdf pcodr_avastin_capecitabine_mcrc_pagfdk.pdf pcodr_avastin_capecitabine_mcrc_fdk_roche.pdf pcodr_avastin_capecitabine_mcrc_ptfdk_ccac.pdf pcodr_avastin_capecitabine_mcrc_coi_ccac.pdf	Nov 13, 2015	Reimbursement Review	Complete	PC0055-000
teduglutide	cdr_SR0459_Revestive.pdf SR0459_Revestive_complete_Jul-29_16.pdf SR0459_Revestive_CL_Report.pdf SR0459_Revestive_PE_Report.pdf SR0459_Revestive_PI_Submissions.pdf	Oct 30, 2015	Reimbursement Review	Complete	SR0459-000
lumacaftor/ivacaftor	cdr_SR0471_Orkambi.pdf SR0471_complete_Orkambi-Oct-28-16.pdf SR0471_Orkambi_CL_Report.pdf SR0471_Orkambi_PE_Report.pdf SR0471_Orkambi_PI_Submissions.pdf	Oct 30, 2015	Reimbursement Review	Complete	SR0471-000
Denosumab	cdr_SF0453_Prolia.pdf SF0453_complete_RFA-Prolia_May-25-16_e.pdf SF0453_Prolia_RfA_Review_Report.pdf SF0453 Prolia_PI_Submissions.pdf	Oct 26, 2015	Reimbursement Review	Complete	SF0453-000
Iclusig for Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia – Details	pcodr_provfund_iclusig_cml-all.pdf pcodr_ponatinib_iclusig_cml-all_fn_rec.pdf pcodr_ponatinib_iclusig_cml-all_fn_cgr.pdf pcodr_ponatinib_iclusig_cml-all_fn_egr.pdf pcodr_ponatinib_iclusig_cml_all_in_rec.pdf pcodr_ponatinib_iclusig_cml-all_pagfdk.pdf pcodr_ponatinib_iclusig_cml-all_fdk_ariad.pdf	Oct 20, 2015	Reimbursement Review	Complete	PC0056 -000
Omalizumab (Drug Plan Submission)	cdr_SR0457_Xolair_Resub.pdf SR0457_complete_Xolair_Resub-May_19_16.pdf SR0457_Xolair_Resub_PI_Submissions.pdf SR0457_Xolair_Resubmission_CL_Report_e.pdf SR0457_Xolair_Resubmission_PE_Report_e.pdf	Oct 6, 2015	Reimbursement Review	Complete	SR0457-000
Denosumab (Drug Plan Submission)	cdr_SR0433-001_Xgeva.pdf SR0433-001_complete_Xgeva_OST-Mar-28_16-e.pdf SR0433-001 Xgeva_FWG_OST_PE_Report.pdf SR0433-001 Xgeva_FWG_OST_CL_Report.pdf SR0433-001_Xgeva_PI_Submissions.pdf	Oct 2, 2015	Reimbursement Review	Complete	SR0433-001
Elosulfase alfa	SR0456 Vimizim Resubmission.pdf SR0456_complete_Vimizim_May-26_16.pdf SR0456_Vimizim_Resubmission_CL_Report.pdf SR0456_Vimizim_Resubmission_PE_Report.pdf SR0456_Vimizim_Resubmission_PI_Submissions_Consolidated_validated.pdf	Oct 1, 2015	Reimbursement Review	Complete	SR0456-000
Tafinlar & Mekinist in combo for Metastatic Melanoma - Details	pcodr-provfund_tafinlarmekinist_melanoma.pdf pcodr_tafinlar_mekinist_metmelanoma_fn_rec.pdf pcodr_tafinlar_mekinist_metmelanoma_fn_cgr.pdf pcodr_tafinlar_mekinist_metmelanoma_fn_egr.pdf pcodr_tafinlar_mekinist_metmelanoma_in_rec.pdf pcodr_tafinlar_mekinist_metmelanoma_pagfdk.pdf pcodr_tafinlar_mekinist_metmelanoma_fdk_gsm.pdf pcodr_tafinlar_mekinist_metmelanoma_ptfdk_mnc.pdf pcodr_tafinlar_mekinist_metmelanoma_ptfdk_sysf.pdf pcodr_tafinlar_mekinist_metmelanoma_coi_mnc.pdf pcodr_tafinlar_mekinist_metmelanoma_coi_sysf.pdf	Sep 29, 2015	Reimbursement Review	Complete	PC0053-000
Nexavar for Metastatic Progressive Differentiated Thyroid Carcinoma - Details	pcodr-provfund_sorafenib_nexavar_dtc.pdf pcodr_sorafenib_nexavar_dtc_fn_rec.pdf pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf pcodr_sorafenib_nexavar_dtc_fn_egr.pdf pcodr_sorafenib_nexavar_dtc_in_rec.pdf pcodr_sorafenib_nexavar_dtc_pagfdk.pdf pcodr_sorafenib_nexavar_dtc_fdk_bayer.pdf pcodr_sorafenib_nexavar_dtc_ptfdk_tcc.pdf pcodr_sorafenib_nexavar_dtc_coi_tcc.pdf	Sep 29, 2015	Reimbursement Review	Complete	PC0049-000
Perjeta or Perjeta-Herceptin Combo Pack for Neoadjuvant Breast Cancer - Details	pcodr-provfund_pertuzumab_perjeta_nbc.pdf pcodr_pertuzumab_perjeta_nbc_fn_rec.pdf pcodr_pertuzumab_perjeta_nbc_fn_cgr.pdf pcodr_pertuzumab_perjeta_nbc_fn_egr.pdf pcodr_pertuzumab_perjeta_nbc_in_rec.pdf pcodr_pertuzumab_perjeta_nbc_pagfdk.pdf pcodr_pertuzumab_perjeta_nbc_fdk_roche.pdf pcodr_pertuzumab_perjeta_nbc_ptfdk_cbcn.pdf pcodr_pertuzumab_perjeta_nbc_coi_cbcn.pdf	Sep 29, 2015	Reimbursement Review	Complete	PC0050-000
Stivarga Resubmission for mCRC - Details	pcodr-provfund_regorafenib_stivarga-resub_mcrc.pdf pcodr_regorafenib_stivarga_resub_mcrc_fn_rec.pdf pcodr_regorafenib_stivarga_resub_mcrc_fn_cgr.pdf pcodr_regorafenib_stivarga_resub_mcrc_fn_egr.pdf pcodr_regorafenib_stivarga_resub_mcrc_in_rec.pdf pcodr_regorafenib_stivarga_resub_mcrc_pagfdk.pdf pcodr_regorafenib_stivarga_resub_mcrc_fdk_bayer.pdf pcodr_regorafenib_stivarga_resub_mcrc_ptfdk_ccac.pdf pcodr_regorafenib_stivarga_resub_mcrc_coi_ccac.pdf	Sep 29, 2015	Reimbursement Review	Complete	PC0046-000
Elbasvir/grazoprevir	cdr_SR0454_grazoprevir_elbasvir.pdf SR0454_complete_Zepatier_May_25-16.pdf SR0454_Zepatier_CL_Report.pdf SR0454_Zepatier_PE_Report.pdf SR0454_grazoprevir+elbasvir_PI_Submissions_Consolidated_validated.pdf	Sep 23, 2015	Reimbursement Review	Complete	SR0454-000
Insulin glargine	cdr_SE0451_Basaglar.pdf SE0451_complete_Basaglar-Apr_19-16-e.pdf SE0451_Basaglar_PI_Submissions.pdf SE0451_Basaglar_SEB_Report.pdf	Sep 4, 2015	Reimbursement Review	Complete	SE0451-000
Zydelig for Chronic Lymphocytic Leukemia – Details	pcodr-provfund_idelalisib-zydelig-cll.pdf pcodr_idelalisib_zydelig_cll_fn_rec.pdf pcodr_idelalisib_zydelig_cll_fn_cgr.pdf pcodr_idelalisib_zydelig_cll_fn_egr.pdf Idelalisib Initial Recommendation_ 2015-07-30_AC_30July2015_FinalPost.pdf pcodr_idelalisib_zydelig_cll_pagfdk.pdf pcodr_idelalisib_zydelig_cll_API.pdf pcodr_idelalisib_zydelig_cll_ptfdk_lc.pdf pcodr_idelalisib_zydelig_cll_coi_lc.pdf pcodr_idelalisib_zydelig_cll_ptfdk_cllpag_llsc.pdf pcodr_idelalisib_zydelig_cll_coi_cllpag.pdf pcodr_idelalisib_zydelig_cll_coi_llsc.pdf	Sep 2, 2015	Reimbursement Review	Complete	PC0057-000
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide	cdr_SR0449_ECFTAF.pdf SR0449_Genvoya_CL_Report-e.pdf SR0449_Genvoya_PE_Report-e.pdf SR0449_complete_Genvoya-March_22-16_e.pdf SR0449 Genvoya_PI_Submissions.pdf	Aug 27, 2015	Reimbursement Review	Complete	SR0449-000
Deferiprone	cdr_SR0448_Ferriprox.pdf SR0448_cdr_complete_Ferriprox_March-23-16_e.pdf SR0448_Ferriprox_CL_Report.pdf SR0448_Ferriprox_PE_Report.pdf SR0448_Ferriprox_PI_Submissions.pdf	Aug 26, 2015	Reimbursement Review	Complete	SR0448-000
Filgrastim	cdr_SE0446_Grastofil.pdf SE0446_cdr_complete_Grastofil_March-22-16_e.pdf SE0446_Grastofil_SEB_Report.pdf SE0446_Grastofil_PI_Submissions.pdf	Aug 12, 2015	Reimbursement Review	Complete	SE0446-000
Ombitasvir/ paritaprevir/ ritonavir	cdr_SR0444_ombitasvir-paritaprevir-ritonavir.pdf SR0444_cdr_complete_Technivie_March-23-16_e.pdf SR0444_Technivie_CL_Report.pdf SR0444_Technivie_PE_Report.pdf SR0444 Technivie - PI_Submissions_Consolidated_validated.pdf	Aug 7, 2015	Reimbursement Review	Complete	SR0444-000
Xalkori Resubmission for First Line Advanced NSCLC - Details	pcodr-provfund_xalkori_nsclc1stline.pdf pcodr_xalkori_1stln_nsclc_fn_rec.pdf pcodr_xalkori_1stln_nsclc_fn_cgr.pdf pcodr_xalkori_1stln_nsclc_fn_egr.pdf pcodr_xalkori_1stln_nsclc_in_rec.pdf pcodr_xalkori_1stln_nsclc_pagfdk.pdf pcodr_xalkori_1stln_nsclc_fdk_pfizer.pdf pcodr_xalkori_1stln_nsclc_coi_ola.pdf pcodr_xalkori_1stln_nsclc_coi_lcc.pdf	Aug 6, 2015	Reimbursement Review	Complete	PC0054-000
Sacubitril/valsartan	cdr_SR0447_sacubitril_valsartan.pdf SR0447_complete_Entresto-Mar-22_e.pdf SR0447_Entresto_CL_Report.pdf SR0447_Entresto_PE_Report.pdf SR0447 Entresto Template_PI_Submissions_Consolidated_validated.pdf	Aug 4, 2015	Reimbursement Review	Complete	SR0447-000
Xtandi First Line mCRPC - Details	pcodr-provfund_xtandi_mcrpc1stline.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_rec.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_cgr.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_egr.pdf pcodr_enzalutamide_xtandi_1stln_mcrcp_in_rec.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_pagfdk.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fdbk_astellas.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_ptfdk_pcc.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_coi_pcc.pdf	Jul 31, 2015	Reimbursement Review	Complete	PC0044-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81